UBS Group’s Entero Therapeutics ENTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.22K | Sell |
6,851
-12,474
| -65% | -$15K | ﹤0.01% | 7643 |
|
|
2025
Q1 | $27.8K | Buy |
19,325
+16,816
| +670% | +$24.2K | ﹤0.01% | 6701 |
|
|
2024
Q4 | $4.68K | Buy |
+2,509
| New | +$4.68K | ﹤0.01% | 7496 |
|
|
2024
Q3 | – | Sell |
-150
| Closed | -$552 | – | 8881 |
|
|
2024
Q2 | $552 | Buy |
+150
| New | +$552 | ﹤0.01% | 7709 |
|
|
2024
Q1 | – | Sell |
-512
| Closed | -$6.46K | – | 8710 |
|
|
2023
Q4 | $6.46K | Buy |
512
+484
| +1,729% | +$6.1K | ﹤0.01% | 6494 |
|
|
2023
Q3 | $488 | Buy |
+28
| New | +$488 | ﹤0.01% | 7313 |
|
|
2023
Q2 | – | Sell |
-68
| Closed | -$11K | – | 7526 |
|
|
2023
Q1 | $11K | Buy |
68
+34
| +100% | +$5.5K | ﹤0.01% | 6442 |
|
|
2022
Q4 | $12.6K | Buy |
34
+29
| +580% | +$10.7K | ﹤0.01% | 7065 |
|
|
2022
Q3 | $3K | Buy |
+5
| New | +$3K | ﹤0.01% | 8492 |
|
|
2022
Q1 | – | Sell |
-5
| Closed | -$82K | – | 9692 |
|
|
2021
Q4 | $82K | Buy |
+5
| New | +$82K | ﹤0.01% | 5409 |
|
|
2021
Q3 | – | Hold |
0
| – | -$10K | – | 7695 |
|
|
2021
Q2 | – | Hold |
0
| – | -$5K | – | 6962 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 7303 |
|
|
2020
Q2 | – | Hold |
0
| – | -$1K | – | 7359 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6886 |
|
|
2019
Q3 | – | Hold |
0
| – | -$4K | – | 7197 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6589 |
|
|
2019
Q1 | – | Hold |
0
| – | -$12K | – | 7166 |
|
|
2018
Q4 | – | Hold |
0
| – | -$15K | – | 6228 |
|
|
2018
Q3 | – | Hold |
0
| – | -$10K | – | 6053 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6226 |
|
|
2018
Q1 | – | Hold |
0
| – | -$7K | – | 7094 |
|
|
2017
Q4 | – | Hold |
0
| – | -$12K | – | 6270 |
|
|
2017
Q3 | – | Hold |
0
| – | -$11K | – | 5886 |
|
|
2017
Q2 | – | Hold |
0
| – | -$12K | – | 5787 |
|
|
2017
Q1 | – | Hold |
0
| – | -$3K | – | 5591 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6449 |
|